Astrazeneca Plc · LSE:AZN
Astrazeneca — J.P. Morgan 41st Annual Healthcare Conference 2023
18 slides from Astrazeneca's conference presentation, Jan 9, 2023
Slide 1: J.P. Morgan 41st Annual Healthcare Conference
J.P. Morgan 41st Annual Healthcare Conference Aradhana Sarin Executive Director and Chief Financial Officer 9 January 2023
Slide 2: Forward-looking statements
Forward-looking statements AstraZeneca (hereafter ‘the Group’) provides the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expe
Slide 3: Science-led, patient-centered
Science-led, patient-centered Developing innovative medicines for millions globally Science and Diverse therapy Strength across primary, Committed to people, innovation led area focus specialty and rare planet and society Environmental protection 179 projects in our pipeline Oncology BioPharmaceutic
Slide 4: Entrepreneurial culture, focused on helping the world
Our people and values Culture case study: our response to the COVID-19 pandemic We continued our clinical Entrepreneurial We follow the science trials around the world and delivered medicines to patients culture, focused We put patients first on helping the We partnered with Oxford University to dev
Slide 5: Strong financials
Strong financials Double digit growth in Oncology, BioPharmaceuticals and Rare Disease driving earnings growth and cash generation Net Cash Flow From Operating Total Revenue Core EPS Activities $37.4bn $8. 0bn $7.4bn $5.29 $5.28 $33.1bn $7. 0bn $6.0bn $26.6bn $4.02 $6. 0bn $24.4bn $3.50 $5. 0bn $4.8
Slide 6: Capital allocation priorities
Capital allocation priorities Effective deployment of capital to ensure opportunities for further growth Strong investment grade rating Reinvestment in the business Medical Affairs and other Discovery Long term: A Long term: A3 Early-stage Short term: A-2 Short term: P-2 Late-stage development devel
Slide 7: Strengthening scientific leadership
Strengthening scientific leadership Extensive R&D investment in cutting-edge platforms and technology ‘Growth Through Innovation’ Enhancing our Better Pioneering Creating the investing in four areas to create the understanding of predictions of new approaches to clinical next disease biology clinica
Slide 8: Continuing momentum in commercial execution
Continuing momentum in commercial execution across all therapy areas, into new diseases and geographies Oncology BioPharmaceuticals Rare Disease TR: 24% GROWTH (CER) TR: 16% GROWTH (CER) TR: 10% GROWTH (CER)* 9M 2022 blockbusters with double digit growth fastest growing SGLT2i globally approved in t
Slide 9: AstraZeneca positioned to lead in CVRM
AstraZeneca positioned to lead in CVRM AstraZeneca to acquire CinCor Pharma to strengthen cardiorenal pipeline Enhancing our position in CVRM The clinical burden of treatment resistant hypertension Developing and delivering innovative, life-changing medicines and solutions for the millions of people
Slide 10: Baxdrostat: addresses a large unmet need in cardiorenal disease
Baxdrostat: addresses a large unmet need in cardiorenal disease A potential best-in-class ASI for treatment resistant hypertension Baxdrostat (CIN-107) – a highly selective, • Hypertension: high-risk factor for stroke, CAD, heart attack and CKD; current treatment options limited aldosterone synthase
Slide 11: 2022: An incredible year of clinical success
2022: An incredible year of clinical success Exceptional delivery of best-in-industry pipeline Positive Phase III data readouts, selected Enhertu DESTINY-Breast04 Ultomiris – CHAMPION-NMOSD Farxiga – DELIVER HER2-low breast cancer neuromyelitis optica spectrum disorder HFpEF eplontersen – NEURO-TTRa
Slide 12: Key upcoming newsflow and selected next wave pipeline
Key upcoming newsflow and selected next wave pipeline Next wave early pipeline H1 2023 H2 2023 AZD8205 – B7H4 Top1i ADC Imfinzi – biliary tract cancer (TOPAZ-1) (EU) Beyfortus – RSV (US) Imfinzi – liver cancer (1L) (HIMALAYA) (EU) Soliris – gMG (CN) AZD0486 – CD3xCD20 TCE Enhertu – HER2-low breast c
Slide 13: AstraZeneca: positioned to deliver industry-leading growth
AstraZeneca: positioned to deliver industry-leading growth Optimised LoE profile Growth from robust portfolio and an innovative pipeline All growth rates at CER1 Mid- and long-term durability Industry-leading 2021-2025 low Low twenties % growth post 2025 double digit increase in 2022 CAGR2 Ultomiris
Slide 14: AstraZeneca: a sustainable, long-term growth opportunity
AstraZeneca: a sustainable, long-term growth opportunity Multiple organic levers drive momentum and sustain attractive growth profile Industry-leading execution Strong track-record across key therapy areas Committed to delivering Low double-digit revenue Late-stage pipeline success Robust breadth an
Slide 15: Closing comments and Q&A
Closing comments and Q&A 15
Slide 16: Investor Relations
Andy Barnett Josie Afolabi Head of Investor Relations Oncology andrew.barnett@astrazeneca.com josie.afolabi@astrazeneca.com Morgan Sanford Christer Gruvris Investor Oncology BioPhamaceuticals (CVRM), Finance morgan.sanford@astrazeneca.com and Fixed Income christer.gruvris@astrazeneca.com Relations P
Slide 17: Important information about the tender offer
Important information about the tender offer The tender offer described in this presentation has not yet commenced. This presentation is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any shares of the common stock of CinCor or any other se
Slide 18: Confidentiality Notice
Confidentiality Notice This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or dis
AstraZeneca — J.P. Morgan 41st Annual Healthcare Conference 2023 on 6ix